Breaking News


Efficacy of systemic therapies for moderate-severe plaque psoriasis: Systematic review and meta-analysis


The efficacy of psoriasis treatments was compared following a systematic review of randomized controlled trials (RCTs) and a meta-analysis. Twenty-two RCTs involving 9,917 patients with moderate-severe plaque psoriasis were identified; each trial used the Psoriasis Area and Severity Index (PASI) as the primary efficacy outcome. PASI 50, PASI 75 and PASI 90 responses (decreases in the baseline PASI score by 50% or more, 75 or 90%) were calculated, but only the relative risks (RRs) of the PASI 75 response are discussed here. Tumor necrosis factor inhibitors (TNFIs) were the most likely agents to achieve PASI 75 with a mean RR of 15.57 vs. 9.24 and 5.65 for systemic and T-cell therapies, respectively. ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list